125 results
8-K
EX-99.1
EQ
Equillium Inc
9 May 24
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
4:05pm
preserving non-pathogenic signaling. This approach is expected to avoid the broad immuno-suppression and off-target safety liabilities that may … studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; risks related to Ono’s
8-K
EX-99.1
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
at the annual meetings of both ASN and ACR. The presentations highlighted a well-tolerated safety profile and data that demonstrated high complete … -pathogenic signaling. This approach is expected to avoid the broad immuno-suppression and off-target safety liabilities that may be associated with other
8-K
EX-99.2
fhvxk2l va95ts
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
EX-99.1
q8vtf x2g
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
EX-99.1
0cmu tmks
16 Oct 23
Regulation FD Disclosure
8:05am
8-K
a6e4k5du3
16 Oct 23
Regulation FD Disclosure
8:05am
424B5
3r5j hnvb3m
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
u538084s0r
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
EX-99.1
t0osxapt7tpy
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
8-K
EX-99.1
jmnzqdibqc30k8z
23 Dec 22
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
4:11pm
425
upi442
6 Dec 22
Business combination disclosure
7:02am
8-K
jsej25ujz mxs4khhpgu
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am
8-K
EX-99.1
vmd5h
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am
8-K
EX-99.2
p88bz274
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am